News und Analysen
European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) granted marketing authorization for LORVIQUA® (lorlatinib, available in the U.S. under the brand name LORBRENA®) as
Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment
Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the conditional
Charles River Expands Strategic Partnership With SAMDI Tech
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of their strategic partnership with Chicago, Illinois-based SAMDI Tech, Inc. Under the existing partnership
Agilent and A*STAR’s SIFBI Sign Research Collaboration Agreement to Advance Singapore Agri-Food Industry
Agilent Technologies Inc. (NYSE: A) recently signed a Research Collaboration Agreement (RCA) with the Singapore Institute of Food and Biotechnology Innovation (SIFBI) outlining their collaboration
AMN Healthcare Commitment Supports Underserved Nurses and Nurse Wellness
In line with its commitment to the health and wellbeing of nurses, and for advancing diversity, equality, equity, and inclusion in the nursing profession, AMN Healthcare is donating to support the
Go365® by Humana Announces Winners of Fourth Annual National Step Challenge, Resulting in 7.2 Billion Steps Taken and One Million Meals Donated to Feeding America®
Today, leading health and well-being company, Humana Inc. (NYSE: HUM), announced the winners of its 2021 Go365 National Step Challenge – a health and wellness competition that focuses on improving
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an Omicron-based vaccine
Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, announced the presentation
Dexcom Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for February 10, 2022 at 4:30 p.m. Eastern Time.
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2021 financial results after market close on Thursday, February 10, 2022. Management will hold a
Agilent Announces the Innovative Seahorse XF Pro Analyzer
Agilent Technologies Inc. (NYSE: A) today announced the release of the Agilent Seahorse XF Pro Analyzer, featuring new pharma-oriented workflow solutions incorporating advanced experimental design
U.S. Food and Drug Administration Expands Deployment of Waters Corporation Software to Support its Medical Products Testing Labs
Waters Corporation (NYSE: WAT) today announced the U.S. Food and Drug Administration’s (FDA) Office of Regulatory Affairs (ORA) has purchased Waters™ Empower™ Chromatography Data Software (CDS) and
Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency
Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Biologics License
AMN Healthcare to Hold Fourth Quarter and Full Year 2021 Earnings Conference Call on Thursday, February 17, 2022
AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its fourth quarter and full year 2021 financial results and first quarter 2022 outlook on Thursday, February
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on January 18, 2022 the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement
Premier, Inc. Declares Quarterly Cash Dividend
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.20 per share of Class A common
Charles River Laboratories Schedules Fourth-Quarter 2021 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2021 financial results on Wednesday, February 16th, before the market opens. A conference call
Simulations Plus Partners with Large Pharmaceutical Company to Drive Advancements to the GastroPlus Mechanistic Oral Absorption Model
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced a new
Charles River and Valo Health Announce Strategic Partnership to Provide Clients with Access to AI-Enabled Drug Discovery Solutions
Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, LLC (“Valo”), the technology company using human-centric data and computation powered by artificial intelligence (AI) to
PINC AI™ Launches INsights, an Enhanced Technology Offering for Customized, On-Demand Healthcare Analytics
PINC AI™, the technology and services platform of Premier, Inc (NASDAQ: PINC), today launched INsights, an enhanced self-service healthcare solution for the creation of customized, on-demand
Waters beschleunigt quantitative Massenspektrometrie mit neuer Anwendung auf der Informatikplattform waters_connect
ie Waters Corporation (NYSE:WAT) gab heute bekannt, dass sie ihre Informatik-Softwareplattform waters_connect™ erweitert, um Kunden bei der Analyse von Nahrungsmittel- und Umweltproben mit
U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved CIBINQO® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for
Premier Inc.’s Contigo Health Expands Provider-Sponsored Health Plan Offerings Through New Partnership With OhioHealthy
Contigo Health LLC, a subsidiary of Premier Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced a new partnership with OhioHealthy Plans, LLC
Agilent to Webcast First-Quarter Fiscal Year 2022 Financial Results Presentation
Agilent Technologies Inc. (NYSE: A) will release first-quarter fiscal year 2022 financial results after the stock market closes on Tuesday, Feb. 22. The company will host a live webcast of its
Simulations Plus Enters New Collaboration with Leading Animal Health Company
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced a new
Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for